The SiBionics-backed heart disease device developer secured $28.4m in a round led by SDIC Gaoxin Industrial Investment.
Insight Lifetech, a China-based heart disease treatment developer backed by medical device provider SiBionics, has received RMB200m ($28.4m) in series B-plus funding, DealStreetAsia has reported.
The round was led by SDIC Gaoxin Industrial Investment, a vehicle of state-owned investment holding group State Development and Investment, and included Green Pine Capital Partners, Efung Capital, Sequoia Capital China, Lotus Lake Capital and Sherpa Venture Partners.
Founded in 2015, Insight Lifetech is developing systems to diagnose and treat coronary heart disease. Its product…